Rezolute Company
Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases. The company is advancing a diversified portfolio including RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy; AB101 (Phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 targeting Diabetic Macular Edema (DME) and RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.
Technology:
Cancer
Industry:
Geroscience
Headquarters:
Louisville, Colorado, United States
Zip:
11-50
Founded Date:
2010-01-01
Employees Number:
11-50
Acquisitions Number:
10
Investors Number:
311595068
Total Funding:
311595068
Estimated Revenue:
2012-05-08
Last Funding Date:
Post-IPO Equity
Last Funding Type:
info@antriabio.com
Register and Claim Ownership